LeadingBiotech: Europe CEO is part of the Informa Connect Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Jasper Bos joined Merck’s previous biopharma fund of M Ventures in 2009 and transitioned to Senior Vice President and Managing Director M Ventures in 2019. At M Ventures, Jasper Bos supported (amongst others) the early successful investments and exits in ObsEva (NASDAQ), EpiTherapeutics (sale to Gilead), and was an initiator of Prexton Therapeutics, which was acquired early 2018 by Luendbeck for close to US1,100bn, Calypso Biotech, Inthera, Metabomed and Asceneuron. He holds a PhD in Pharmacy from the University of Groningen, the Netherlands, and has previously worked in private equity and at the Netherlands Vaccine Institute. Jasper published over 35 articles on health economics, vaccines and mathematical modelling.